ArticleFrontiers in endocrinology2024
Network pharmacology combined with Mendelian randomization analysis to identify the key targets of renin-angiotensin-aldosterone system inhibitors in the treatment of diabetic nephropathy.
Article in Frontiers in endocrinology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 19 citations in OpenAlex.
- Renal proteomics of male offspring exposed to maternal protein restriction: molecular, epigenetic, and nephron-specific signatures of metabolic programming.Journal of physiology and biochemistry · 2026Article
- Review
- Salvia miltiorrhiza (Danshen) and its extracts in the alternative treatment of diabetic nephropathy: mechanisms and clinical perspectives.Journal of natural medicines · 2026Review
- Elucidating the PTK2-Targeted Anti-Hepatocellular Carcinoma Effects ofCurrent issues in molecular biology · 2026Article
- Study on the Potential Mechanism of Bisphenol A-induced Human Diabetic Nephropathy Based on Network Toxicology and Molecular Docking.Endocrine, metabolic & immune disorders drug targets · 2026Article
- Identification and Validation of the Prognostic Value of PTTG1-Related Genes in Hepatocellular Carcinoma by Mendelian Randomization and Single-Cell Transcriptome Analysis.Iranian journal of biotechnology · 2026Article
- Therapeutic targets for diabetic nephropathy identified by druggable genome mendelian randomization: the role of the gut microbiota-metabolite axis.Frontiers in endocrinology · 2026Article
- Association of chaperone-mediated autophagy with the mechanisms of vascular calcification in diabetic nephropathy.Renal failure · 2025Article
- Serum uric acid to high‑density lipoprotein cholesterol ratio as a novel predictor of diabetic nephropathy: a cross‑sectional analysis of NHANES 2011-2018.Clinical and experimental medicine · 2025Article
- Andrographolide as a Multi-Target Therapeutic Agent in Diabetic Nephropathy: Insights into STAT3/PI3K/Akt Pathway Modulation.Biomolecules & therapeutics · 2025Article
- Article
- Liuwei Dihuang pills ameliorate renal injury in experimental type 2 diabetes mellitus rat by regulating host-gut microbiota interaction.Frontiers in pharmacology · 2025Article
- Identification and Verification of Biomarkers Related to Polyamine Metabolism in Diabetic Nephropathy.Journal of diabetes research · 2025Article
- Acupuncture for diabetic nephropathy: mechanisms, clinical evidence, and future perspectives.Frontiers in endocrinology · 2025Review
- Exploration and Validation of Key Genes and Immune Infiltration in Alcoholic Hepatitis.Journal of inflammation research · 2025Article
- Yiqi Yangyin Tongluo Recipe Alleviates Diabetic Kidney Disease Through AGE-RAGE Signalling Axis.Diabetes, metabolic syndrome and obesity : targets and therapy · 2025Article
- Ursolic Acid Ameliorates Diabetic Nephropathy by Inhibiting JAK2/STAT3-Driven Ferroptosis: Mechanistic Insights from Network Pharmacology and Experimental Validation.Drug design, development and therapy · 2025Article
- The pathogenesis of diabetic kidney disease and the therapeutic potential of bioactive substances.Frontiers in pharmacology · 2025Review
- Molecular mechanisms and multi-target therapeutic strategies of diabetic nephropathy: from pathogenesis to precision interventions.Frontiers in pharmacology · 2025Review
- Mendelian randomization analysis reveals causal factors behind diabetic nephropathy: evidence, opportunities, and challenges.Frontiers in endocrinology · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Diabetic Nephropathy (DN) is one of the microvascular complications of diabetes. The potential targets of renin-angiotensin-aldosterone system (RAAS) inhibitors for the treatment of DN need to be explored. Methods: The GSE96804 and GSE1009 datasets, 729 RAAS inhibitors-related targets and 6,039 DN-related genes were derived from the public database and overlapped with the differentially expressed genes (DN vs. normal) in GSE96804 to obtain the candidate targets. Next, key targets were screened via the Mendelian randomization analysis and expression analysis. The diagnostic nomogram was constructed and assessed in GSE96804. Additionally, enrichment analysis was conducted and a 'core active ingredient-key target-disease pathway' network was established. Finally, molecular docking was performed. Results: In total, 60 candidate targets were derived, in which Conclusion:
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.